Psyence BioMed Chief of Global Impact to speak at Psychedelic Science 2025
Psyence BioMed’s Chief of Global Impact, Mary-Elizabeth Gifford, joins PS2025’s Business Track as a featured speaker at the world’s top psychedelic science event.
Psyence BioMed Regains Full Compliance with Nasdaq Continued Listing Requirements
Psyence Biomedical Ltd. announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows a successful compliance hearing held on May 29, 2025.
Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial
Psyence Biomed announced the finalization of its service agreement with Southern Star Research Pty Ltd (“Southern Star Research”), an award-winning, full-service Australian Contract Research Organization (CRO).
Insights Care Magazine – Tony Budden
Discover the future of mental health care through the eyes of Tony Budden, CEO of PsyLabs, in his thought-provoking feature in Insights Care Magazine. As a pioneer in the development of nature-derived psychedelic compounds like psilocybin and ibogaine, PsyLabs—working in close partnership with Psyence Biomed—is advancing groundbreaking solutions for substance use disorders and other mental health challenges.
Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Psyence BioMed announced today that it received a notification letter dated April 16, 2025, from the Listings Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Rule”). The Staff's determination is based on the closing bid price of the Company’s common shares being below $1.00 for 30 consecutive business days from March 5, 2025 through April 15, 2025.
Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement
Psyence BioMed today announced a strategic follow-on investment of USD $500,000 into PsyLabs, a privately-held company specializing in the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for research, clinical trials, and drug development.
Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia
New partnership strengthens Psyence BioMed’s global clinical trial capabilities, accelerating the development of psilocybin-assisted therapy for adjustment disorder
Psyence Biomedical LTD Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
Corporate Webinar – April 10, 2025
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies
Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein
Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapies